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Abstract
Background: Aluminium (Al) toxicity was frequent in the 1980s in patients ingesting Al containing phosphate
binders (Alucaps) whilst having HD using water potentially contaminated with Al. The aim of this study was to
determine the risk of Al toxicity in HD patients receiving Alucaps but never exposed to contaminated dialysate
water.
Methods: HD patients only treated with Reverse Osmosis(RO) treated dialysis water with either current or past
exposure to Alucaps were given standardised DFO tests. Post-DFO serum Al level > 3.0 μmol/L was defined to
indicate toxic loads based on previous bone biopsy studies.
Results: 39 patients (34 anuric) were studied. Mean dose of Alucap was 3.5 capsules/d over 23.0 months. Pre-DFO
Al levels were > 1.0 μmol/L in only 2 patients and none were > 3.0 μmol/L. No patients had a post DFO Al levels
> 3.0 μmol/L. There were no correlations between the serum Al concentrations (pre-, post- or the incremental rise
after DFO administration) and the total amount of Al ingested.
No patients had unexplained EPO resistance or biochemical evidence of adynamic bone.
Conclusions: Although this is a small study, oral aluminium exposure was considerable. Yet no patients
undergoing HD with RO treated water had evidence of Al toxicity despite doses equivalent to 3.5 capsules of
Alucap for 2 years. The relationship between the DFO-Al results and the total amount of Al ingested was weak (R
2
= 0.07) and not statistically significant. In an era of financial prudence, and in view of the recognised risk of excess
calcium loading in dialysis patients, perhaps we should re-evaluate the risk of using Al-based phosphate binders in
HD patients who remain uric.
Background
The importance of preventing hyperphosphataemia is
well established and its management is outlined in the
bone and mineral metabolism section of the K-DIGO
[1]. The evolution of phosphate binder therapy in
patients with chronic renal disease has followed an
interesting pattern over the past 35 years. Historically,
aluminium salts were used to treat hyperphosphataemia,
but safety concerns about accumulation and toxic effects
including osteomalacia and encephalopathy meant there
was a switch to calcium based binders (carbonate or
acetate) [2].
However, the accumulation of aluminium was found
in dialysis patients at a time when haemodialysis was
conducted against water that might have contained alu-
minium (concentration depending on the local
water) [3,4]. Haemodialysis using Reverse-Osmosis (RO)
treated water has been the norm since the late 1990’s
[5] and it remains to be determined if clinically signifi-
cant aluminium accumulation occurs when aluminium
based phosphate binders are ingested without the con-
founding factor of aluminium-contaminated dialysis.
All water for haemodialysis at Barts and The London
NHS Trust was treated by RO since early 1990’s. We con-
temporaneously recorded the medications of dialysis
patients and so are able to identify current patients that
were treated with oral aluminium. We quantified aluminium
ingested by patients who started HD since Jan 2002 (and
therefore never exposed to Al-contaminated dialysis water).
To assess the risk of toxic accumulation of aluminium
in these identified patients, we performed a validated
low-dose desferrioxamine (DFO) test [6]
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This study followed guidelines set out by the local
Ethics Committee; DFO tests were performed on
patients for clinical reasons to determine level of alumi-
nium toxicity in patients with previous exposure.
All patients that started haemodialysis since Jan 2002
and were still on treatment at 1
st June 2009 were identi-
fied through our electronic patient records. We
reviewed and quantified the amounts of aluminium that
were prescribed for these patients. The load of alumi-
nium was calculated on the basis that each Alucap™
capsule contained 475 mg of dried aluminium hydro-
xide (equivalent to 174 mg of aluminium). These
patients underwent a low-dose DFO test performed
during a 48 hr inter-dialytic period. Briefly, 500 mg of
desferrioximine (DFO) was administered intravenously
at the end of their dialysis. Pre-DFO and 48 hr post
dose (pre-dialysis) aluminium concentrations were mea-
sured. Evidence of significant in vivo aluminium load
was defined if baseline serum aluminium concentration
was > 1.0 μmol/L, whilst post DFO levels > 3.0 μmol/L
was defined to indicate significant risk of aluminium
toxicity. During and after the DFO test, haemodialysis
staff were asked to report any adverse events that might
be related (with particular emphasis on infections and
pyrexia of unknown origins but we did not specifically
examine visual acuity).
Formal documentation of residual renal function of
haemodialysis patients was not routine practise at our
institution. However, for the purpose of this study, we
classified patients to anuric if they self reported their
RRF as < 200 mls/day.
Laboratory Methods
Serum Aluminium levels were measured by ICPMS. The
instrument used was an XSERIES2 ICPMS (Thermo
Fisher, Hemel Hempstead, UK). Ultra pure water [Elga
UHQII unit, High Wycombe, UK)] and ICPMS quality
reagents were used. The assay standard was multi-ele-
ment containing 9.27 μmol/L Aluminium and elements
Cadmium, Copper, Lead, Manganese, Selenium and
Zinc. Control sera was obtained from Bio-Stat Diagnos-
tics, UK. The controls and tests 125 μl (plasma, LiHep)
were thoroughly mixed with 5 ml of internal standard/
diluent containing 20 ppb Gallium,10 ppb Indium, 10
ppb Rhodium, 5 ppb Scandium in 1% Nitric Acid, 0.2%
Propan-2-ol, 0.2% Butan-1-ol and 0.005% Triton X-100.
Aluminium mass 27 was monitored with the internal
standard ion scandium mass 45. The signal for zero
diluent was usually less than 3000 with 90,000 counts
for the 9.27 μmol/L standard.
The detection limit for the assay was 0.1 μmol/L and
within-batch CV [n = 6] was:- at 0.5 μmol/L 3.7%, 1.1
μmol/L 6.4%, 4.3 μmol/L 5.3%, respectively and the
inter-batch CV [n = 13] at 0.4 μmol/L 17%, 1.3 μmol/L
6.0%, 3.9 μmol/L 4.5% and 7.4 μmol/L 4.0%..
Statistics
This was mostly a descriptive study of the results of
DFO tests performed in patients prescribed oral alumi-
nium-based phosphate binders. However, univariate
regression analysis was performed to compare the pre-
DFO and post-DFO serum aluminium level with the
total cumulative prescribed aluminium load. We also
compared the increment in serum aluminium level after
DFO with the prescribed aluminium load.
Results
We identified 39 current haemodialysis patients that ful-
filled our criteria of starting HD since Jan 2002 and having
prior prescriptions of oral aluminium salts as a phosphate
binder. The mean total cumulative dose of aluminium
hydroxide was 1.2 kg (range: 71 g - 7.15 kg) whilst the
median cumulative dose was 848 g (with 1
st and 3
rd quar-
tile values of 252 g and 1.85 kg respectively, Figure 1a).
The mean (SEM) duration of treatment of the patients
was 23.0 months (range 1 - 74 months); with the mean
dose of Alucap that was prescribed being 3.5 capsules/day.
At the time the DFO test was performed, 13 patients were
still taking the drug (mean duration off oral aluminium
was 12.9 months) - Figure 1b. There were no reported
adverse events related to the DFO tests.
The mean (SEM) age of the patients was 56.5 (2.4) yrs
old. None of the patients had been prescribed calcium
citrate. Taken as a group, at the time of DFO test, there
Figure 1 The amount of aluminium prescribed (load and
duration) and the duration off the drug prior to DFO test.
Pepper et al. BMC Nephrology 2011, 12:55
http://www.biomedcentral.com/1471-2369/12/55
Page 2 of 5was little evidence that these patients had hypoparathyr-
oidism; mean (SEM) serum PTH was 48.5 (6.8) pM
whilst mean (SEM) Hb concentration was maintained at
9.8 (0.3) g/dl. Thirty-four patients self reported that they
had a daily urine output of less than 200 mLs.
Baseline serum Al concentrations were generally low
in all patients, Figure 2. No patients had serum Al levels
above 3.0 μmol/L and only 2 patients had concentra-
tions above 1.0. These 2 patients had cumulative doses
of 1.36 kg and 1.85 kg and both were anuric.
The mean (SEM) baseline Al concentration was 0.39
(0.04) μmol/L. Only 1 patient who had sickle cell disease
had a concomitant serum ferritin concentration > 1000
μg/l. This patient had a baseline serum Al concentration
of 0.1 μmol/L and no clinical evidence of Al Bone Dis-
ease (PTH was 31.8 pmol/L and Alk Phos was 5.8 times
the upper limit of normality).
The post DFO serum Al concentration increased from
a mean (SEM) of 0.39 (0.04) to 0.85 (0.08)μmol/L as
would be expected (p < 0.00001), Figure 2. Nevertheless,
none reached the threshold of > 3.0 μmol/L although
12/43 patients had a level > 1.0 μmol/L. Neither of the
2 patients that had evidence of significant baseline Al
concentrations (baseline Al level > 1.0 μmol/L) had
greater than 3-fold increments in Al level after DFO
(incremental rises were from baselines of 1.3 and 1.2
μmol/L to 2.4 and 2.8 μmol/L respectively).
When we compared the post DFO serum Al concen-
trations with the cumulative Al load that was prescribed
to the patient, we found there was no statistically signifi-
cant correlation (p = 0.10, Figure 3). Any relationship
that did exist was weak (R
2 = 0.07).
Discussion
It has now been almost 2 decades since changes in clini-
cal practises have led to aluminium phosphate binders
being replaced by other binders and reverse osmosis
(RO) water being used for the preparation of dialysate
fluid. High serum aluminium levels are now rare in the
dialysis patients [7].
However, aluminium-based binders are highly effective
at binding phosphate and causes relatively mild gastro-
intestinal discomfort. Fears of re-introducing aluminium
toxicity remains despite the fact that many believe alu-
minium-contaminated dialysate water were a greater
contributor to the historic problem than oral phosphate
binder usage; in an epidemiological survey of dialysis
units, concentration of aluminium in dialysate water
correlated with the incidence of both aluminium bone
disease and encephalopathy [8].
We have attempted to gain insight into the whether
oral intake of aluminium hydroxide will cause significant
toxicity by studying patients that were prescribed signifi-
cant amounts as part of their clinical care.
All baseline serum Al concentrations of patients
tested showed levels that were below the threshold
that would indicate potentially toxic Aluminium levels
(> 3.0 μmol/L). However, we know that defining a
baseline serum aluminium concentration threshold to
diagnose toxic aluminium accumulation is difficult [9]
not least because aluminium can be sequestered in
bone. Thus, in order to determine total body Al load,
we decided to perform DFO tests on all at-risk
patients. To maximise sensitivity, we used a post-DFO
Al threshold of > 3.0 μmol/L to denote patients at risk
of “high total body accumulation”. There are different
DFO protocols in the literature with doses ranging
f r o m5t o8 0m g / k g[ 1 0 ] .T om a x i m i s es e n s i t i v i t y ,w e
wanted to give a larger DFO dose than proposed by
D’H a e s ee ta l[ 1 1 ]( 5m g / k g ) ,b u tf e l tt h er i s ko fh i g h
dose DFO (30-80 mg/kg) to be unwarranted in a
screening program. We therefore decided to use 500
mg- a dose validated against bone biopsies [6] to show
a false positive rate of 11% and a false negative rate of
0% (i.e. a negative DFO test had a 100% predictive
value). It is particularly reassuring that all patients in
our cohort had a negative DFO test.
Although the number of patients studied is small, it is
interesting that there were no statistically significant
correlations between the serum aluminium concentra-
tions (pre-, post- or the incremental rise after DFO
administration) and the total amount of aluminium
ingested (although this may because of our small study
size). However, even if a statistically significant correla-
tion were to be found in a very large study, we still
argue that it would not be clinically significant as our R
2
value was only 0.07. We suggest that the aluminium
load coming from phosphate binders is likely to be
dwarfed by other sources such as drinking water and
foods.
Figure 2 Serum Aluminium levels of patients exposed to oral
Al based phosphate binders pre and post-DFO test.
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tance as defined by by Greenwood et al; Hb < 10.0 g/dl
and EPO dose > 23,000 IU/wk [12]. This was higher
than the 5% reported in the DOPPS survey that
included US and European patients, but, clear alterna-
tive reasons could be found in 2 (sickle cell disease and
highly inflamed at time of blood sampling) whilst tun-
nelled dialysis catheters were present in 4 other patients.
Moreover, there are many confounders (our patients
were likely to be prescribed aluminium because of poor
phosphate control and thus EPO resistance may be sec-
ondary to hyperparathyroidism rather than Aluminium
toxicity).
We interpret our results to suggest that the use of alu-
minium-based phosphate binders in the era of RO-trea-
ted dialysis water appears to be safe. However, our study
has many limitations that need to be acknowledged.
Many patients were prescribed oral aluminium over a
long period of time and we did not collect contempora-
neous data about their residual renal function. We
determined if patients were anuric at the time of DFO
testing, but this would not have identified patients that
recently became anuric (but who were uric for the
majority of their treatment period). Secondly, interpreta-
tions of our results are hampered by the lack of a “con-
trol” group. These would have been matched HD
patients who had never been prescribed aluminium-
based phosphate binders. Thirdly, not all patients were
still taking oral aluminium at the time of their DFO
test. However, the aluminium has a very long biological
half-life and DFO can mobilise the bone stores. Another
limitation of our study is the small size and the absence
of bone biopsy data. Finally, this was a study of patients
that survived after being prescribed aluminium. It is
possible that we could not find toxic levels because of
selection bias (patients with aluminium toxicity would
have died). However, we think this is unlikely; there
were no reported cases of suspected aluminium toxicity
in our unit. Moreover, even if selection bias existed, we
should still have found a significant correlation between
aluminium load and DFO results.
In an era of financial prudence, Mudge et al have re-
evaluated the risk of using aluminium based phosphate
binders in haemodialysis patients who remain uric [13].
We found DFO testing was simple to conduct on a hae-
modialysis unit and well-tolerated by the patients. The
sensitivity and specificity of DFO test are superior to
random serum aluminium concentrations for the diag-
nosis of aluminium bone disease and as an indicator of
total body load. We did not perform specific ophthal-
mologic tests but we were confident that there were no
increased incidences of infections or haemodynamic
instability related to DFO administration. We believe
that DFO testing should be used more frequently if the
use of aluminium hydroxide is increased.
Conclusions
Although this is a small study, oral aluminium exposure
was considerable. Yet no patients undergoing HD with
RO treated water had evidence of Al toxicity despite
Figure 3 Correlation between the total cumulative Al (in kg) ingested by patients and their 48 hr post DFO serum Al concentration.
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The relationship between the DFO-Al results and the
total amount of Al ingested was weak (R
2 =0 . 0 7 )a n d
not statistically significant. In an era of financial pru-
dence, and in view of the recognised risk of excess cal-
cium loading in dialysis patients, perhaps we should re-
evaluate the risk of using Al-based phosphate binders in
HD patients who remain uric.
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